CORCEPT THERAPEUTICS INC (CORT)
US2183521028 - Common Stock
CORCEPT THERAPEUTICS INC
NASDAQ:CORT (12/20/2024, 8:03:39 PM)
After market: 52.55 +1.15 (+2.24%)51.4
+0.25 (+0.49%)
Company Profile
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. The company is headquartered in Redwood City, California and currently employs 352 full-time employees. The company went IPO on 2004-04-15. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Company Info
CORCEPT THERAPEUTICS INC
101 Redwood Shores Parkway
Redwood City CALIFORNIA 94025
P: 16506888803
CEO: Joseph K. Belanoff
Employees: 352
Website: https://www.corcept.com/
CORT News
3 days ago - ChartmillInvestors should take note of NASDAQ:CORT, a growth stock that remains attractively priced.CORCEPT THERAPEUTICS INC (NASDAQ:CORT) stands out as a growth opportunity that won't break the bank.
7 days ago - Corcept Therapeutics IncorporatedCorcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism10 days ago - Corcept Therapeutics IncorporatedCorcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
11 days ago - ChartmillExploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
11 days ago - ChartmillNASDAQ:CORT, a strong growth stock, setting up for a breakout.CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating.
11 days ago - Corcept Therapeutics IncorporatedCorcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)CORT Twits
Here you can normally see the latest stock twits on CORT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
